Invesco Ltd. lifted its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 86.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 499,949 shares of the company's stock after buying an additional 231,470 shares during the period. Invesco Ltd. owned about 0.96% of PROCEPT BioRobotics worth $40,256,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the company. Lord Abbett & CO. LLC boosted its position in PROCEPT BioRobotics by 45.3% during the third quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company's stock valued at $59,974,000 after acquiring an additional 233,430 shares during the last quarter. Perpetual Ltd bought a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at about $66,972,000. Oak Ridge Investments LLC grew its stake in PROCEPT BioRobotics by 24.0% during the fourth quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company's stock worth $2,420,000 after purchasing an additional 5,817 shares during the period. SG Americas Securities LLC increased its holdings in PROCEPT BioRobotics by 295.8% in the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company's stock worth $531,000 after purchasing an additional 4,931 shares in the last quarter. Finally, Chicago Capital LLC lifted its stake in PROCEPT BioRobotics by 44.5% in the fourth quarter. Chicago Capital LLC now owns 379,582 shares of the company's stock valued at $30,564,000 after buying an additional 116,931 shares during the period. 89.46% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
PRCT has been the subject of several research reports. Truist Financial reduced their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Morgan Stanley cut their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $91.43.
View Our Latest Analysis on PROCEPT BioRobotics
Insider Activity
In related news, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,455 shares of company stock worth $368,322. Corporate insiders own 17.40% of the company's stock.
PROCEPT BioRobotics Price Performance
PRCT stock traded up $0.22 during mid-day trading on Friday, hitting $53.03. 868,416 shares of the stock were exchanged, compared to its average volume of 782,183. The business has a fifty day moving average price of $59.16 and a 200 day moving average price of $74.66. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of -27.19 and a beta of 1.09. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. On average, sell-side analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.
PROCEPT BioRobotics Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
